The frequency of resistant mutant virus before antiviral therapy

AIDS

Volumn 12, Issue 5, 1998, Pages 461-465

  Ribeiro, Ruy M ^a   Bonhoeffer, Sebastian ^b   Nowak, Martin A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

Antiviral therapy; Mathematical model; Resistant mutant; Viral load

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; POINT MUTATION; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MATHEMATICS; MODELS, BIOLOGICAL; POINT MUTATION; VIRAL LOAD;

EID: 0032568196     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00006     Document Type: Article

References (31)

1. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
2. Ho DD, Neumann AU, Perelson AS, Cher W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
4. Nowak MA, Bonhoeffer S, Loveday C, et al.: HIV-1 dynamics: results confirmed. Nature 1995, 375:193
5. Loveday C, Kay S, Tenant-Flowers M, et al.: HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995, 345:820-024.
6. Eron JJ, Benoit SL, MacArthur RD, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
7. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
8. Lafeuillade A, Poggi C, Sayada C, Pellegrino P, Profizi N: Focusing on the second phase of plasma HIV-1 RNA clearance [letter]. AIDS 1997, 11:264-266.
9. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
10. Coffin JM: HIV viral dynamics. AIDS 1996, 10 (suppl 3):S75-S84.
11. McLean AR, Nowak MA: Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992, 6:71-79.
12. Nowak MA, May RM: AIDS pathogenesis: mathematical models of HIV and SIV infections. AIDS 1993, 7 (suppl 1):S3-S18.
13. Bonhoeffer S, Nowak MA: Pre-existence and emergence of drug resistance in HIV-1 infection. Proc R Soc Lond B Biol Sci 1997, 264:631-637.
14. Bonhoeffer S, May RM, Shaw GM, Nowak MA: Models of virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997, 94:6971-6976.
15. McLean AR, Emery VC, Webster A, Griffiths PD: Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 1991, 5:485-489.
16. Nowak MA, Anderson RM, McLean AR, Wolfs T, Goudsmit J, May RM: Antigenic diversity thresholds and the development of AIDS. Science 1991, 254:963-969.
17. Bonhoeffer S, Coffin JM, Nowak MA: Human immunodeficiency virus drug therapy and virus load. J Virol 1997, 71:3275-3278.
18. Frost SDW, McLean AR: Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994, 8:323-332.
19. Stilianakis NI, Boucher CAB, De Jong MD, van Leeuwen R, Schuurman R, De Boer RJ: Clinical data sets of human immunodeficiency virus type-1 reverse transcriptase resistant mutants explained by a mathematical model. J Virol 1997, 71:161-168.
20. Nowak MA, Anderson RM, Boerlijst MC, Bonhoeffer S, May RM, McMichael AJ: HIV evolution and disease progression. Science 1996, 274:1008-1010.
21. Nowak MA, Bonhoeffer S, Shaw GM, May RM: Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997, 184:203-217.
22. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1585.
23. Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA: Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci USA 1996, 93:7247-7251.
24. De Boer RC, Boucher CAB: Anti-CD4 therapy of AIDS suggested by mathematical models. Proc R Soc Lond B Biol Sci 1996, 263:899-905.
25. Boerlijst MC, Bonhoeffer S, Nowak MA: Viral quasi-species and recombination. Proc R Soc Lond B Biol Sci 1996, 263:1577-1584.
26. Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than the predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 29:5087-5094.
27. Goudsmit J, De Ronde A, Ho DD, Perelson AS: Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996, 70:5662-5664.
28. Nájera I, Holguín A, Quiñones-Mateu ME, et al.: pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
29. Eigen M, Schuster P: The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. Naturwissenschaften 1977, 64:541-565.
30. Nowak MA, Schuster P: Error thresholds of replication in finite populations. Mutation frequencies and the onset of Muller's ratchet. J Theor Biol 1989, 137:375-395.
31. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.